文献速递眼底病与葡萄膜炎

结核性葡萄膜炎接受抗结核治疗患者的临床特征与结局:结核性眼病协作研究(COTS)-1

Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项回顾性多国队列研究纳入25家眼科转诊中心2004年1月1日至2014年12月31日诊断结核性葡萄膜炎并接受抗结核治疗、随访至少1年的801例患者(1272只眼)。治疗失败102例(12.7%)。多因素分析显示,玻璃体混浊、雪堤样改变和脉络膜受累与治疗失败风险升高相关。作者指出研究受回顾性方法限制。

要点

  • 801例结核性葡萄膜炎患者中治疗失败102例(12.7%)。
  • 全葡萄膜炎、中间葡萄膜炎和前葡萄膜炎的治疗失败风险高于后葡萄膜炎。
  • 多因素分析中玻璃体混浊、雪堤样改变和脉络膜受累与治疗失败风险升高相关。

核心结论

  • 接受抗结核治疗的结核性葡萄膜炎患者治疗失败率较低,全葡萄膜炎伴玻璃体和脉络膜受累者治疗失败风险更高,但这些发现受回顾性方法限制。

研究设计与样本

  • 回顾性多国队列研究,纳入25家眼科转诊中心2004年1月1日至2014年12月31日诊断结核性葡萄膜炎并接受抗结核治疗、随访至少1年的患者,共801例(1272只眼)。

主要发现

  • 801例患者平均(标准差)年龄40.5(14.8)岁,男性413例(51.6%)、女性388例(48.4%),亚洲人577例(73.6%)。
  • 661例中有498例(75.3%)无已知系统性结核病史,801例中471例(58.8%)为双侧受累。
  • 常见体征包括玻璃体混浊(1153例中523例,45.4%)、视网膜血管炎(874例中374例,42.8%)和脉络膜受累(651例中419例,64.4%)。
  • 单因素回归分析中,中间葡萄膜炎(HR 2.21,95%CI 1.07-4.55,P=0.03)、前葡萄膜炎(HR 2.68,95%CI 1.32-2.35,P=0.006)和全葡萄膜炎(HR 3.28,95%CI 1.89-5.67,P<0.001)的治疗失败风险均显著高于后葡萄膜炎分布。
  • 多因素Cox比例风险回归分析中,玻璃体混浊的校正HR为2.98(95%CI 1.50-5.94,P=0.002),雪堤样改变的校正HR为3.71(95%CI 1.18-11.62,P=0.02),脉络膜受累的校正HR为2.88(95%CI 1.22-6.78,P=0.02)。

关键数值与推荐

  • 治疗失败定义为完成抗结核治疗后6个月内炎症持续或复发、无法将口服皮质类固醇减至小于10 mg/d或将局部皮质类固醇滴眼液减至小于每日2滴,和/或顽固性炎症需要使用保类固醇的免疫抑制治疗。
  • 单因素分析中,玻璃体混浊存在与不存在相比具有统计学显著关联(HR 1.95,95%CI 1.26-3.02,P=0.003)。
  • 单因素分析中,双侧受累与单侧受累相比HR为1.50(95%CI 0.96-2.35),但未达统计学显著(P=0.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些发现受回顾性方法限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HIV pandemic. Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the existing uncertainty in the diagnosis of TB uveitis may perpetuate missed opportunities to address systemic TB. OBJECTIVE: To examine the clinical features of TB uveitis and the associations with response to antitubercular therapy (ATT). DESIGN, SETTING, AND PARTICIPANTS: This retrospective multinational cohort study included patients from 25 ophthalmology referral centers diagnosed with TB uveitis and treated with ATT from January 1, 2004, through December 31, 2014, with a minimum follow-up of 1 year. MAIN OUTCOMES AND MEASURES: Treatment failure, defined as a persistence or recurrence of inflammation within 6 months of completing ATT, inability to taper oral corticosteroids to less than 10 mg/d or topical corticosteroid drops to less than 2 drops daily, and/or recalcitrant inflammation necessitating corticosteroid-sparing immunosuppressive therapy. RESULTS: A total of 801 patients (1272 eyes) were studied (mean [SD] age, 40.5 [14.8] years; 413 [51.6%] male and 388 [48.4%] female; 577 [73.6%] Asian). Most patients had no known history (498 of 661 [75.3%]) of systemic TB. Most patients had bilateral involvement (471 of 801 [58.8%]). Common clinical signs reported include vitreous haze (523 of 1153 [45.4%]), retinal vasculitis (374 of 874 [42.8%]), and choroidal involvement (419 of 651 [64.4%]). Treatment failure developed in 102 of the 801 patients (12.7%). On univariate regression analysis, the hazard ratios (HRs) associated with intermediate uveitis (HR, 2.21; 95% CI, 1.07-4.55; P = .03), anterior uveitis (HR, 2.68; 95% CI, 1.32-2.35; P = .006), and panuveitis (HR, 3.28; 95% CI, 1.89-5.67; P < .001) were significantly higher compared with posterior distribution. The presence of vitreous haze had a statistically significant association (HR, 1.95; 95% CI, 1.26-3.02; P = .003) compared with absence of vitreous haze. Bilaterality had an associated HR of 1.50 (95% CI, 0.96-2.35) compared with unilaterality (HR, 1 [reference]), although this finding was not statistically significant (P = .07). On multivariate Cox proportional hazards regression analysis, the presence of vitreous haze had an adjusted HR of 2.98 (95% CI, 1.50-5.94; P = .002), presence of snow banking had an adjusted HR of 3.71 (95% CI, 1.18-11.62; P = .02), and presence of choroidal involvement had an adjusted HR of 2.88 (95% CI, 1.22-6.78; P = .02). CONCLUSIONS AND RELEVANCE: A low treatment failure rate occurred in patients with TB uveitis treated with ATT. Phenotypes and test results are studied whereby patients with panuveitis having vitreous and choroidal involvement had a higher risk of treatment failure. These findings are limited by retrospective methods. A prospectively derived composite clinical risk score might address this diagnostic uncertainty through holistic and standardized assessment of the combinations of clinical features and investigation results that may warrant diagnosis of TB uveitis and treatment with ATT.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol. 2017. PMID: 29075752. doi:10.1001/jamaophthalmol.2017.4485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。